Gross margin of the leading manufacturers of human vaccines in China 2011
Gross margin of the leading manufacturers of human vaccines in China in 2011
The statistic shows the gross margin of the leading manufacturers of human vaccines in China in 2011. The gross margin is calculated by deducting manufacturing costs from revenue. It is predominantly expressed in percent of sales. The gross margin does not include the costs incurred in research and development and marketing processes. In 2011, the gross margin of vaccine manufacturer Zhifei Biological amounted to 58.89 percent.
Gross margin of the leading manufacturers of human vaccines in China in 2011
Source
More information
Statistics on "Pharmaceutical trends in Europe"
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Proactive patients in reviewing select health information and issues 2013
- Pharmaceutical companies by highest net margin 2014
- Best time for pharmaceutical companies to contact patient 2013
- Top ten pharmaceutical merger and acquisition deals by value 2014
- Leading European vaccine products by market share 2015-2022
- Usage volume influenza vaccination Japan 2008-2016
- Total prescription drug revenue in Europe from top 10 companies 2015
- Digital health strategy for pharmaceutical companies in the future 2013-2020
- Leading pharmaceutical companies by global anti-viral revenue 2017 and 2024
- Colombia: top drug store chains in 2017. by size
- Global vaccine market revenues 2014-2020
- Enterprise value of top companies in non-oncology rare disease therapeutics 2017
- Importance of digital health strategy objectives for pharma companies 2013
- Digital health strategy priorities for pharma companies 2013
- Brazil: leading pharmaceutical & cosmetics companies 2017, by revenue
Statistics on "Pharmaceutical trends in Europe"
Related topics
About Statista
